Exclusivity deals for hepatitis C drugs by pharmacy benefit managers and
a major health plan have raised concerns that the decision of which
drug is best for a patient is being taken away from clinicians.
While thankful that the companies are ensuring access to treatment, some patient advocates find the trend unsettling.
Franciscus, executive director of the Hepatitis C Support Project,
called the agreements “a scary precedent.” “The insurance companies and
dispensing companies like CVS and Express Scripts
are deciding what drugs hepatitis C patients are being prescribed
instead of physicians making medical decisions based on solid science,”
Labels: alan franciscus, interviews, patient safety, treatment options